Islet cell transplantation

Seminars in Pediatric Surgery

Volumn 23, Issue 2, 2014, Pages 83-90

  McCall, Michael ^a   Shapiro, A M James ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cells; Diabetes; Islets; Pancreas; Transplantation

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ALLOTRANSPLANTATION; ARTICLE; DISEASE SEVERITY; DONOR SELECTION; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DYSFUNCTION; LEUKOPENIA; MOUTH ULCER; NEOPLASM; PANCREAS ISLET TRANSPLANTATION; PATIENT SELECTION; PRIORITY JOURNAL; SURGICAL TECHNIQUE; TREATMENT INDICATION; TREATMENT OUTCOME; CHILD; DIABETES MELLITUS, TYPE 1; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATIONS; PROCEDURES;

CHILD; DIABETES MELLITUS, TYPE 1; DONOR SELECTION; HUMANS; ISLETS OF LANGERHANS TRANSPLANTATION; PATIENT SELECTION; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

EID: 84902172792     PISSN: 10558586     EISSN: 15329453     Source Type: Journal    
DOI: 10.1053/j.sempedsurg.2014.03.006     Document Type: Article

References (63)

1. King H., Aubert R.E., Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21(9):1414-1431.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329(14):977-986.
3. Keen H. The diabetes control and complications trial (DCCT). Health Trends 1994, 26(2):41-43.
4. Nathan D.M., Lachin J., Cleary P., et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003, 348(23):2294-2303.
5. Kelly W.D., Lillehei R.C., Merkel F.K., et al. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery 1967, 61(6):827-837.
6. Williams P.W. Notes on diabetes treated with extract and by grafts of sheep's pancreas. Br Med J 1894, 1303-1304.
7. Moskalewski S. Isolation and culture of the islets of Langerhans of the guinea pig. Gen Comp Endocrinol 1965, 44:342-353.
8. Ballinger W.F., Lacy P.E. Transplantation of intact pancreatic islets in rats. Surgery 1972, 72(2):175-186.
9. Kemp C.B., Knight M.J., Scharp D.W., et al. Transplantation of isolated pancreatic islets into the portal vein of diabetic rats. Nature 1973, 244(5416):447.
10. Scharp D.W., Kemp C.B., Knight M.J., et al. The use of ficoll in the preparation of viable islets of langerhans from the rat pancreas. Transplantation 1973, 16(6):686-689.
11. Walsh T.J., Eggleston J.C., Cameron J.L. Portal hypertension, hepatic infarction, and liver failure complicating pancreatic islet autotransplantation. Surgery 1982, 91(4):485-487.
12. Alejandro R., Cutfield R.G., Shienvold F.L., et al. Natural history of intrahepatic canine islet cell autografts. J Clin Invest 1986, 78(5):1339-1348.
13. Horaguchi A., Merrell R.C. Preparation of viable islet cells from dogs by a new method. Diabetes 1981, 30(5):455-458.
14. Noel J., Rabinovitch A., Olson L., et al. A method for large-scale, high-yield isolation of canine pancreatic islets of Langerhans. Metabolism 1982, 31(2):184-187.
15. Sutton R., Gray D.W., Burnett M., et al. Metabolic function of intraportal and intrasplenic islet autografts in cynomolgus monkeys. Diabetes 1989, 38(suppl 1):182-184.
16. Cattral M.S., Warnock G.L., Kneteman N.M., et al. Transplantation of purified single-donor canine islet allografts with cyclosporine. Transplantation 1989, 47(4):583-587.
17. Ricordi C., Lacy P.E., Scharp D.W. Automated islet isolation from human pancreas. Diabetes 1989, 38(suppl 1):140-142.
18. Lake S.P., Bassett P.D., Larkins A., et al. Large-scale purification of human islets utilizing discontinuous albumin gradient on IBM 2991 cell separator. Diabetes 1989, 38(suppl 1):143-145.
19. Scharp D.W., Lacy P.E., Santiago J.V., et al. Insulin independence after islet transplantation into type I diabetic patient. Diabetes 1990, 39(4):515-518.
20. Socci C., Falqui L., Davalli A.M., et al. Fresh human islet transplantation to replace pancreatic endocrine function in type 1 diabetic patients. Report of six cases. Acta Diabetol 1991, 28(2):151-157.
21. Warnock G.L., Kneteman N.M., Ryan E.A., et al. Continued function of pancreatic islets after transplantation in type I diabetes. Lancet 1989, 2(8662):570-572.
22. Tzakis A.G., Ricordi C., Alejandro R., et al. Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet 1990, 336(8712):402-405.
23. Ricordi C., Tzakis A.G., Carroll P.B., et al. Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation 1992, 53(2):407-414.
24. Benhamou P.Y., Oberholzer J., Toso C., et al. Human islet transplantation network for the treatment of type I diabetes: first data from the Swiss-French GRAGIL consortium (1999-2000). Groupe de Recherche Rhin Rhjne Alpes Geneve pour la transplantation d'Ilots de Langerhans. Diabetologia 2001, 44(7):859-864.
25. Brendel M.H.B., Schulz A., Bretzel International Islet Transplant Registry Report 2001, University of Giessen, Germany, [pp 1].
26. Shapiro A.M., Lakey J.R., Ryan E.A., et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000, 343(4):230-238.
27. Shapiro A.M., Ricordi C., Hering B.J., et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006, 355(13):1318-1330.
28. Lakey J.R., Warnock G.L., Rajotte R.V., et al. Variables in organ donors that affect the recovery of human islets of Langerhans. Transplantation 1996, 61(7):1047-1053.
29. Ihm S.H., Matsumoto I., Sawada T., et al. Effect of donor age on function of isolated human islets. Diabetes 2006, 55(5):1361-1368.
30. Deng S., Vatamaniuk M., Huang X., et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 2004, 53(3):624-632.
31. Lakey J.R., Rajotte R.V., Warnock G.L., et al. Human pancreas preservation prior to islet isolation. Cold ischemic tolerance. Transplantation 1995, 59(5):689-694.
32. de Boer J., De Meester J., Smits J.M., et al. Eurotransplant randomized multicenter kidney graft preservation study comparing HTK with UW and Euro-Collins. Transpl Int 1999, 12(6):447-453.
33. Hering B.J., Matsumoto I., Sawada T., et al. Impact of two-layer pancreas preservation on islet isolation and transplantation. Transplantation 2002, 74(12):1813-1816.
34. Goss J.A., Schock A.P., Brunicardi F.C., et al. Achievement of insulin independence in three consecutive type-1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet isolation center. Transplantation 2002, 74(12):1761-1766.
35. Wolters G.H., Vos-Scheperkeuter G.H., van Deijnen J.H., et al. An analysis of the role of collagenase and protease in the enzymatic dissociation of the rat pancreas for islet isolation. Diabetologia 1992, 35(8):735-742.
36. Wolters G.H., Vos-Scheperkeuter G.H., Lin H.C., et al. Different roles of class I and class II Clostridium histolyticum collagenase in rat pancreatic islet isolation. Diabetes 1995, 44(2):227-233.
37. Johnson P.R., White S.A., London N.J. Collagenase and human islet isolation. Cell Transplant 1996, 5(4):437-452.
38. Bucher P., Mathe Z., Morel P., et al. Assessment of a novel two-component enzyme preparation for human islet isolation and transplantation. Transplantation 2005, 79(1):91-97.
39. Szot G.L., Lee M.R., Tavakol M.M., et al. Successful clinical islet isolation using a GMP-manufactured collagenase and neutral protease. Transplantation 2009, 88(6):753-756.
40. O'Gorman D., Kin T., Imes S., et al. Comparison of human islet isolation outcomes using a new mammalian tissue-free enzyme versus collagenase NB-1. Transplantation 2010, 90(3):255-259.
41. Mehigan D.G., Bell W.R., Zuidema G.D., et al. Disseminated intravascular coagulation and portal hypertension following pancreatic islet autotransplantation. Ann Surg 1980, 191(3):287-293.
42. Ryan E.A., Shandro T., Green K., et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 2004, 53(4):955-962.
43. Gangemi A., Salehi P., Hatipoglu B., et al. Islet transplantation for brittle type 1 diabetes: the UIC protocol. Am J Transplant 2008, 8(6):1250-1261.
44. Hering B.J., Kandaswamy R., Ansite J.D., et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. J Am Med Assoc 2005, 293(7):830-835.
45. Froud T., Ricordi C., Baidal D.A., et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant 2005, 5(8):2037-2046.
46. Froud T., Faradji R.N., Pileggi A., et al. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation 2008, 86(1):36-45.
47. Ghofaili K.A., Fung M., Ao Z., et al. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation 2007, 83(1):24-28.
48. Faradji R.N., Tharavanij T., Messinger S., et al. Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept. Transplantation 2008, 86(12):1658-1665.
49. Froud T., Yrizarry J.M., Alejandro R., et al. Use of D-STAT to prevent bleeding following percutaneous transhepatic intraportal islet transplantation. Cell Transplant 2004, 13(1):55-59.
50. Biarnes M., Montolio M., Nacher V., et al. Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Diabetes 2002, 51(1):66-72.
51. Owen R.J., Ryan E.A., O'Kelly K., et al. Percutaneous transhepatic pancreatic islet cell transplantation in type 1 diabetes mellitus: radiologic aspects. Radiology 2003, 229(1):165-170.
52. Kaplan B., Schold J., Srinivas T., et al. Effect of sirolimus withdrawal in patients with deteriorating renal function. Am J Transplant 2004, 4(10):1709-1712.
53. Senior P.A., Paty B.W., Cockfield S.M., et al. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 2005, 5(9):2318-2323.
54. Ryan E.A., Paty B.W., Senior P.A., et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005, 54(7):2060-2069.
55. Bellin M.D., Kandaswamy R., Parkey J., et al. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant 2008, 8(11):2463-2470.
56. Investigators TCCCa. The collaborative Islet Transplant Registry Annual Report. 〈〉 ; 2009. http://www.citregistryorg/reports/reportshtm.
57. Warnock G.L., Thompson D.M., Meloche R.M., et al. A multi-year analysis of islet transplantation compared with intensive medical therapy on progression of complications in type 1 diabetes. Transplantation 2008, 86(12):1762-1766.
58. Cure P., Pileggi A., Froud T., et al. Improved metabolic control and quality of life in seven patients with type 1 diabetes following islet after kidney transplantation. Transplantation 2008, 85(6):801-812.
59. Poggioli R., Faradji R.N., Ponte G., et al. Quality of life after islet transplantation. Am J Transplant 2006, 6(2):371-378.
60. Toso C., Shapiro A.M., Bowker S., et al. Quality of life after islet transplant: impact of the number of islet infusions and metabolic outcome. Transplantation 2007, 84(5):664-666.
61. Gonder-Frederick L.A., Clarke W.L., Cox D.J. The emotional, social, and behavioral implications of insulin-induced hypoglycemia. Semin Clin Neuropsychiatry 1997, 2(1):57-65.
62. Patrick A.W., Campbell I.W. Fatal hypoglycaemia in insulin-treated diabetes mellitus: clinical features and neuropathological changes. Diabet Med 1990, 7(4):349-354.
63. Hathout E., Lakey J., Shapiro J. Islet transplant: an option for childhood diabetes?. Arch Dis Child 2003, 88(7):591-594.